SNTI: Senti Bio Net earnings per share (EPS TTM)

Senti Biosciences, Inc. (SNTI) relies on stable biotech demand that remains independent of macroeconomic factors, while maintaining strict eco-ethics and data cybersecurity. The current annual net income per share filters out market noise, with the value of -1.78 expressing the metric level. This price action confirms the success of the US-based operation in creating gene circuits for the targeted destruction of cancer cells.

SNTI (Senti Biosciences, Inc.) Net earnings per one share for the last twelve months history from 04/28/2023 to 11/14/2026

Senti Bio - analytical breakdowns and key metrics (SNTI)

- share price and expert price forecast:

Stock Quotes Senti Biosciences Inc|SNTI - Fair Value Consensus

- market capitalization information:

Market Capitalization Senti Biosciences, Inc.|SNTI - Real Price to Acquire Entire Company

- business book valuation details:

Book Value per Share Senti Biosciences|SNTI - Total Stockholders' Equity|Market Value to Book Value Ratio sentibio.com|SNTI - Aggregate Company Assets

- debt and liquidity data:

- net income and valuation multiples indicators:

SNTI - Company Profit|Projected Future Earnings Senti Biosciences, Inc.|SNTI - Market Cap to Earnings|Projected Price to Earnings Senti Biosciences Inc|SNTI - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Senti Biosciences, Inc.|SNTI - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Senti Biosciences|SNTI - Earnings per share for the trailing year|Quarterly EPS earnings growth sentibio.com|SNTI - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Senti Biosciences, Inc.

- revenue and sales proceeds data:

SNTI - Company Sales Revenue|Projected Sales Volume Senti Biosciences Inc|SNTI - P/S Multiple|Price-to-Projected Revenue Ratio Senti Biosciences, Inc.

General company analysis:sentibio.com (SNTI)

Mass-produced product of Senti Biosciences, Inc.

Bioprocess robotization at Senti Biosciences, Inc. (SNTI) reduces costs, directly impacting bottom-line profitability. This metric measures the portion of net income attributable to a single common share, excluding the influence of the total issuance volume. Investors utilize this filter to assess the operational efficiency of capital amid limited liquidity. Positive dynamics confirm the business's financial stability. By analyzing net income per share over the last 12 months, one can timely identify the trend reversal point.

Analysis of competing companies

LEGN: Net earnings per share for the last 12 months|Earnings per share for the trailing year SANA (sana.com)|AUTL: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Allogene Therapeutics, Inc.|RNAC (Cartesian Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Cellectis Biotherapeutics CLLS|Earnings per share for the last twelve months Caribou Biosciences (CRBU)|Earnings per share for the last twelve months TIL (instilbio.com)|Earnings per share for the last twelve months Genenta Science GNTA|Century Tx - Earnings per share for the last twelve months|JSPR: Net earnings per share for the last 12 months|Earnings per share for the trailing year ADAP (Adaptimmune)|CERO: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Alaunos Therapeutics, Inc. TCRT|ACHL (Achilles Therapeutics PLC) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CARGO Therapeutics Inc. CRGX|Earnings per share for the last twelve months Poseida (PSTX)|2seventy bio, Inc - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) GRCL (Gracell Biotechnologies)